• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

突破性疗法的推出将重塑肾细胞癌市场。

Launch of Breakthrough Therapies Will Reshape Renal Cell Carcinoma Market.

作者信息

Fellner Chris

出版信息

P T. 2016 Aug;41(8):523-5.

PMID:27504069
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4959621/
Abstract

Tyrosine kinase inhibitors (TKIs) are leading systemic therapies for the treatment of renal cell carcinoma. However, programmed death-1 inhibitors, promising new agents in development, may surpass TKIs as the standard of care in the future.

摘要

酪氨酸激酶抑制剂（TKIs）是治疗肾细胞癌的主要全身治疗方法。然而，程序性死亡-1抑制剂作为正在研发的有前景的新型药物，未来可能会超越TKIs成为标准治疗方案。

相似文献

1
Launch of Breakthrough Therapies Will Reshape Renal Cell Carcinoma Market.突破性疗法的推出将重塑肾细胞癌市场。
P T. 2016 Aug;41(8):523-5.
2
Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.脊柱立体定向放射外科联合酪氨酸激酶抑制剂治疗转移性肾细胞癌。
J Neurosurg Spine. 2016 Dec;25(6):766-774. doi: 10.3171/2016.4.SPINE16229. Epub 2016 Jul 8.
3
The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.转移性透明细胞肾细胞癌患者中PD-L1表达与血管内皮生长因子靶向治疗临床结局的相关性
Oncologist. 2015 Nov;20(11):1253-60. doi: 10.1634/theoncologist.2015-0151. Epub 2015 Sep 30.
4
Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma.透明细胞肾细胞癌中酪氨酸激酶抑制剂耐药的分子机制。
Int J Urol. 2022 Dec;29(12):1419-1428. doi: 10.1111/iju.15042. Epub 2022 Sep 19.
5
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.转移性肾细胞癌患者一线和二线酪氨酸激酶抑制剂之间不良事件无显著相关性。
Clin Genitourin Cancer. 2016 Feb;14(1):e19-24. doi: 10.1016/j.clgc.2015.08.002. Epub 2015 Aug 15.
6
Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.酪氨酸激酶抑制剂在肾癌治疗中的应用进展。
Expert Rev Anticancer Ther. 2019 Mar;19(3):259-271. doi: 10.1080/14737140.2019.1573678. Epub 2019 Feb 4.
7
Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications.肾细胞癌对酪氨酸激酶抑制剂耐药的表观遗传改变：从机制到临床应用
Front Genet. 2021 Jan 12;11:562868. doi: 10.3389/fgene.2020.562868. eCollection 2020.
8
Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinoma-Future or the Past?酪氨酸激酶抑制剂在转移性肾细胞癌治疗中的应用——是未来还是过去？
Cancers (Basel). 2022 Aug 3;14(15):3777. doi: 10.3390/cancers14153777.
9
Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.纳武利尤单抗联合伊匹单抗与酪氨酸激酶抑制剂作为转移性肾细胞癌一线治疗的比较：一项多中心回顾性研究。
Int J Clin Oncol. 2021 Jan;26(1):154-162. doi: 10.1007/s10147-020-01797-5. Epub 2020 Oct 16.
10
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.仑伐替尼联合或不联合依维莫司治疗免疫检查点抑制剂和血管内皮生长因子受体酪氨酸激酶抑制剂治疗后转移性肾细胞癌患者。
Oncologist. 2021 Jun;26(6):476-482. doi: 10.1002/onco.13770. Epub 2021 Apr 21.

引用本文的文献

1
The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition.血管内皮生长因子（VEGF）抑制治疗后进展的晚期肾细胞癌患者的治疗格局演变
J Kidney Cancer VHL. 2017 May 11;4(2):10-18. doi: 10.15586/jkcvhl.2017.69. eCollection 2017.

本文引用的文献

1
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.AGS-003 联合舒尼替尼治疗中高危晚期肾细胞癌的自体树突状细胞免疫治疗的生存结果：Ⅱ期研究结果。
J Immunother Cancer. 2015 Apr 21;3:14. doi: 10.1186/s40425-015-0055-3. eCollection 2015.
2
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.随机、对照、双盲、交叉试验评估转移性肾细胞癌患者对帕唑帕尼与舒尼替尼的治疗偏好：PISCES 研究。
J Clin Oncol. 2014 May 10;32(14):1412-8. doi: 10.1200/JCO.2013.50.8267. Epub 2014 Mar 31.
3
PD-1 as a potential target in cancer therapy.PD-1 作为癌症治疗的潜在靶点。
Cancer Med. 2013 Oct;2(5):662-73. doi: 10.1002/cam4.106. Epub 2013 Jul 21.
4
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.帕唑帕尼对比舒尼替尼用于转移性肾细胞癌。
N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989.
5
The epidemiology of renal cell carcinoma.肾细胞癌的流行病学。
Eur Urol. 2011 Oct;60(4):615-21. doi: 10.1016/j.eururo.2011.06.049. Epub 2011 Jul 5.
6
Body mass index, physical activity, and risk of renal cell carcinoma.体重指数、身体活动与肾细胞癌风险
Int J Obes (Lond). 2006 Jun;30(6):940-7. doi: 10.1038/sj.ijo.0803231.